CHICAGO, IL (US), July 2-19 — Researchers have discovered how the genetic defect in fragile X syndrome — a type of autism — delays production of neurons (nerve cells) at a critical time in the embryo's brain development.
You are here
Coverage of the latest news and updates from the field of stem cells and regenerative medicine.
OAKLAND, CA (US), July 2019 — The California Institute for Regenerative Medicine (CIRM) board has approved investing $19.7 million in four awards in its Translational Research program, which helps promising projects complete the testing needed to begin talking to the US Food and
STANFORD, CA (US), July 2019 — Researchers have uncovered how a genetic mutation contributes to a heart disease known as familial dilated cardiomyopathy. Existing drugs correct the defect in heart cells grown in a petri dish, suggesting a new therapeutic target.
OAKLAND, CA (US), July 2019 – A new clinical trial under way that is testing a therapy to treat brain metastases from breast cancers expressing high levels of a protein called HER2. Brain metastases are tumors in the brain that have spread from the original site of the
LONDON (UK), July 2019 — Scientists have identified a new type of cell called a hepatobiliary hybrid progenitor (HHyP) that forms during our early development in the womb.
ROCHESTER, MN (US), July 2019 ― A phase I clinical trial is the first research monitored by the Food and Drug Administration that demonstrates the potential of regenerative therapy for hypoplastic left heart syndrome (HLHS) through collecting, processing and injecting a
BOSTON, MA (US), July 2019 — A new study found that a transcription factor called Slug serves as “command central” for determining breast stem cell health, regulating both stem cell activity and repair of DNA damage.
WÜRZBURG (DE), July 2019 — Scientists at the University Würzburg and University Hospital of Würzburg found that megakaryocytes act as “bouncers,” and thus modulate bone marrow niche properties and cell migration dynamics.
HEIDELBERG (DE), July 2019 — Patients with acute myeloid leukemia (AML) often relapse after apparently successful treatment. Leukemia stem cells that survive the therapy are responsible for the return of the disease.